2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107590
    GR144053 trihydrochloride 1215333-48-4 98%
    GR 144053 trihydrochloride is a selective and non-peptic GPIIb/IIIa inhibitor (IC50=37 nM).
    GR144053 trihydrochloride
  • HY-107630
    RU 26752 76676-33-0 98%
    RU 26752 is a steroid hormone receptor antagonist. RU 26752 can prevent hypertension caused by aldosterone (HY-113313) in rats.
    RU 26752
  • HY-107644
    AQ-RA 741 123548-16-3 98%
    AQ-RA 741 is a potent and selective M 2 antagonist. AQ-RA 741 inhibits the vagally or agonist-induced bradycardia in rats, cats and guinea-pigs. AQ-RA 741 is used in bradycardiac disorders research.
    AQ-RA 741
  • HY-107762
    CGS35066 261619-50-5 98%
    CGS35066 is a potent and selective aminophosphonate inhibitor of endothelin-converting enzyme-1 (ECE-1). CGS 35066 inhibits the activity of human ECE-1 and rat kidney neutral endopeptidase 24.11 (NEP) in vitro with IC50 values of 22 nM and 2.3 μM, respectively.
    CGS35066
  • HY-107901
    Pparδ agonist 1 1902161-12-9 98%
    Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.
    Pparδ agonist 1
  • HY-107918
    Alkaloids, Rauwolfia 8063-17-0 98%
    Alkaloids, Rauwolfia is an extract of the whole root of Rauwolfia serpentina with antihypertensive effect.
    Alkaloids, Rauwolfia
  • HY-107966
    Heparin calcium (MW 15000-19000) 37270-89-6 98%
    Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
    Heparin calcium (MW 15000-19000)
  • HY-108040
    NCX-6560 803728-45-2 98%
    NCX-6560 is an orally active nitric oxide releasing derivative of atorvastatin that inhibits cholesterol biosynthesis and has anti-inflammatory and antithrombotic activity.
    NCX-6560
  • HY-108049
    GW856464 851690-21-6 98%
    GW856464 is an antagonist for MCHR1. GW856464 can be studied in research for cardiovascular diseases and obesity.
    GW856464
  • HY-108055
    Urantide 669089-53-6 98%
    Urantide is a selective and competitive urotensin-II (UT) receptor antagonist peptide (pKB=8.3) that blocks human urotensin-II (hU-II)-induced contractions in rat thoracic aorta ex vivo. Urantide can be used to study the (patho)physiological role of hU-II in the mammalian cardiovascular system.
    Urantide
  • HY-108248
    KU-32 956498-70-7 98%
    KU-32 is a novel, novobiocin-based Hsp90 inhibitor that can protect against neuronal cell death.
    KU-32
  • HY-108304
    Prajmalium bitartrate 2589-47-1 98%
    Prajmalium (bitartrate) (Prajmaline bitartrate) is an antiarrhythmic agent that plays an important role in angina pectoris.
    Prajmalium bitartrate
  • HY-108306
    Moprolol 5741-22-0 98%
    Moprolol ((±)-Moprolol) is an beta-adrenergic receptor blocker, which can be used for research in essential hypertension.
    Moprolol
  • HY-108502
    KC 12291 hydrochloride 181936-98-1 98%
    KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na+ current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo.
    KC 12291 hydrochloride
  • HY-108555
    FR-171113 173904-50-2 98%
    FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC50 of 0.29 μM..
    FR-171113
  • HY-108556
    RWJ-56110 252889-88-6 98%
    RWJ-56110 is a potent, selective, peptide-mimetic inhibitor of PAR-1 activation and internalization (binding IC50=0.44 uM) and shows no effect on PAR-2, PAR-3, or PAR-4. RWJ-56110 inhibits the aggregation of human platelets induced by both SFLLRN-NH2 (IC50=0.16 μM) and thrombin (IC50=0.34 μM), quite selective relative to U46619 (HY-108566). RWJ-56110 inhibits angiogenesis and blocks the formation of new vessels in vivo. RWJ-56110 induces cell apoptosis.
    RWJ-56110
  • HY-108564
    L 655240 103253-15-2 98%
    L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders.
    L 655240
  • HY-108572
    S26948 353280-43-0 98%
    S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC50=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ.
    S26948
  • HY-108582
    Y-27152 127408-30-4 98%
    Y-27152, a proagent of the KATP (Kir6) channel opener Y-26763, is a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
    Y-27152
  • HY-108814
    Ecallantide 460738-38-9 98%
    Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema.
    Ecallantide
Cat. No. Product Name / Synonyms Application Reactivity